Going up?
Not if Will Ferrell’s, Buddy the Elf, was on the elevator with you. LOL!
Love that scene.
However, if you were a Pharma exec and our heads of business development, Babak Alizadeh and Sa’ar Yaniv, happened to encounter you on an elevator, assuming Buddy the button-pushing Elf wasn’t also along for the ride, here’s how these two gentlemen might pitch you on our two lead therapies, RRx-001 (nibrozetone) and AdAPT-001 in less than 60 seconds.
With his trademark cleverness, Babak, after having introduced himself and Sa’ar and their impressive bona fides, might follow with “Hey, we’re going up like patients’ quality of life on RRx-001 (nibrozetone) and AdAPT-001.”
“How so?”, might respond the interested Pharma exec.
“Well,” Babak might say, “I’ll leave AdAPT-001 to Sa’ar, but for RRx-001 it is a first in class, safe, Swiss-army-like small molecule primarily with activity in cancer, chemoradioprotection, and neuroprotection. RRx-001 is currently in two late-stage clinical trials, a Phase 3 for small cell lung cancer (SCLC), and a Phase 2b for severe oral mucositis in head and neck cancer. It has also received 3 prestigious grants for neurodegenerative diseases, Parkinson’s, ALS/MND, and Gulf War Illness.”
At this point Sa’ar would jump in about AdAPT-001. “This is a TGFβ trap-expressing oncolytic adenovirus, AdAPT-001, with dramatic local and systemic responses as single agent and with checkpoint inhibitors in advanced immune refractory tumors in a Phase 1/2 clinical trial. It also seems to protect against checkpoint-inhibitor related immunotoxicities.”
“Wow, very impressive,” might say the Pharma exec, getting off at his floor. “We might have a deal. Let’s follow up. Here’s my business card”.
And that’s how two EpicentRx elevator pitches are done in less than 60 seconds.